Cipla to sell Lilly’s Trulicity, Humalog diabetes treatments in India By Reuters

© Reuters. FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar

BENGALURU (Reuters) – India’s Cipla has signed a deal with Eli Lilly (NYSE:) to sell and distribute two of the U.S. drugmaker’s best-selling diabetes treatments in the country, the companies said in a joint statement on Monday.

Lilly will transfer its rights in India to sell, promote and distribute its Trulicity and Humalog products, while continuing to maintain its existing operating model for the remaining portfolio of its products, the companies said.

The deal will allow Cipla to expand access to the drugs in the country with the second-highest number of diabetic people in the world. India has more than 70 million adults with diabetes, according to government estimates.

Trulicity, a once-weekly shot to control blood sugar through the week, is Lilly’s best-selling drug that raked in sales of $1.54 billion in the second quarter. Its Humalog, a fast-acting insulin injection, is also a key part of its diabetes portfolio.

“Developing strategic partnerships to adopt different operating models is the key to… make innovative medicines available to more people in India,” said Luca Visini, Lilly’s managing director for the Indian subcontinent.

“Cipla has a strong local footprint and is well established to expand access to (Trulicity and Humalog) around India.”

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


*